TCGA-46-3769-01A-01R-0980-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- INTERFERON_ALPHA_RESPONSE+0.390
- PROTEIN_SECRETION+0.390
- ALLOGRAFT_REJECTION+0.330
- DNA_REPAIR+0.310
- MYC_TARGETS_V1+0.300
- PI3K_AKT_MTOR_SIGNALING+0.280
- IL6_JAK_STAT3_SIGNALING+0.270
- INTERFERON_GAMMA_RESPONSE+0.270
- PANCREAS_BETA_CELLS+0.270
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.410
- NOTCH_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- KRAS_SIGNALING_DN-0.250
- MYOGENESIS-0.200
- ESTROGEN_RESPONSE_LATE-0.120
- P53_PATHWAY-0.120
- MITOTIC_SPINDLE-0.090
- APICAL_SURFACE-0.080
- ESTROGEN_RESPONSE_EARLY-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f5174c29-918d-4ad9-bd44-c94463396414 | — | — | 0.832 |
| 2 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.793 |
| 3 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.774 |
| 4 | BS_XF0ZX2B3 | Supratentorial Ependymoma | — | 0.774 |
| 5 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.773 |
| 6 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.759 |
| 7 | e5ae4a47-9a0d-4a70-a7be-40bddeb3d017 | — | — | 0.756 |
| 8 | X16125ffc.4138.408e.9573.cd6c960504cf | — | cohortA1 | 0.755 |
| 9 | 99b069de-d4dd-4c9b-89c3-8b50a59ea334 | — | — | 0.749 |
| 10 | MNG632 | — | — | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |